JP7847587B2 - 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 - Google Patents

血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体

Info

Publication number
JP7847587B2
JP7847587B2 JP2023533847A JP2023533847A JP7847587B2 JP 7847587 B2 JP7847587 B2 JP 7847587B2 JP 2023533847 A JP2023533847 A JP 2023533847A JP 2023533847 A JP2023533847 A JP 2023533847A JP 7847587 B2 JP7847587 B2 JP 7847587B2
Authority
JP
Japan
Prior art keywords
sirp
drug
seq
antibody
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023533847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552375A5 (https=
JP2023552375A (ja
Inventor
ジャウメ ポンズ，
バン ジャネット シム，
エイミー ショー－ルー チェン，
エマ ルース サンガラング，
Original Assignee
エーエルエックス オンコロジー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーエルエックス オンコロジー インコーポレイテッド filed Critical エーエルエックス オンコロジー インコーポレイテッド
Publication of JP2023552375A publication Critical patent/JP2023552375A/ja
Publication of JP2023552375A5 publication Critical patent/JP2023552375A5/ja
Application granted granted Critical
Publication of JP7847587B2 publication Critical patent/JP7847587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/28—PEGylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023533847A 2020-12-06 2021-12-06 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 Active JP7847587B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121964P 2020-12-06 2020-12-06
US63/121,964 2020-12-06
PCT/US2021/062065 WO2022120286A1 (en) 2020-12-06 2021-12-06 Multimers for reducing the interference of drugs that bind cd47 in serological assays

Publications (3)

Publication Number Publication Date
JP2023552375A JP2023552375A (ja) 2023-12-15
JP2023552375A5 JP2023552375A5 (https=) 2024-11-22
JP7847587B2 true JP7847587B2 (ja) 2026-04-17

Family

ID=79287971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533847A Active JP7847587B2 (ja) 2020-12-06 2021-12-06 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体

Country Status (4)

Country Link
US (1) US20220196651A1 (https=)
EP (1) EP4256336A1 (https=)
JP (1) JP7847587B2 (https=)
WO (1) WO2022120286A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
CN114126648A (zh) 2019-05-31 2022-03-01 Alx肿瘤生物技术公司 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法
CN121243368A (zh) 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
KR20230018475A (ko) 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CN116380580A (zh) * 2023-03-15 2023-07-04 中国人民解放军空军军医大学 一种血浆检测前处理方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504524A (ja) 2001-06-28 2005-02-17 ドマンティス リミテッド 二重特異性リガンドとその利用
JP2015504899A (ja) 2012-01-17 2015-02-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
JP2015512034A (ja) 2012-02-15 2015-04-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー
JP2016526909A (ja) 2013-07-31 2016-09-08 アムジエン・インコーポレーテツド Ｆｃ含有ポリペプチドの安定化
JP2017525698A (ja) 2014-08-15 2017-09-07 メルク パテント ゲーエムベーハー Ｓｉｒｐ−アルファ免疫グロブリン融合タンパク質
JP2020503057A (ja) 2016-09-21 2020-01-30 エーエルエックス オンコロジー インコーポレイテッド シグナル調節タンパク質αに対する抗体及び使用方法
WO2020047326A2 (en) 2018-08-31 2020-03-05 ALX Oncology Inc. Decoy polypeptides
JP2020506727A (ja) 2017-02-06 2020-03-05 オリオンズ バイオサイエンス エヌブイ 標的化キメラタンパク質及びその使用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US20100047171A1 (en) * 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
BR112012017164A2 (pt) 2009-12-22 2019-09-24 Novartis Ag proteína de fusão de região constante de anticorpo-cd47 tetravalente
BR112013031762A2 (pt) 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
KR102100388B1 (ko) 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
DK3725807T3 (da) 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
PL3575326T3 (pl) 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
NZ710695A (en) 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
EP3221358B1 (en) 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
MX391051B (es) 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
PT3277821T (pt) 2015-03-31 2019-10-31 Novimmune Sa Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos
CN106146670B (zh) 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
US10358472B2 (en) 2015-05-06 2019-07-23 The Board Of Trustees Of The Leland Stanford Junior University High affinity CD47 analogs
CN114425077A (zh) 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
RU2748401C2 (ru) 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
WO2017053423A1 (en) 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
WO2017068164A1 (en) 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
PT3402820T (pt) 2016-01-11 2020-08-20 Forty Seven Inc Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
BR112018070823A2 (pt) 2016-04-14 2019-02-05 Ose Immunotherapeutics anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
AU2017250029C1 (en) 2016-04-15 2022-03-24 Pfizer Inc. Macrophage stimulation in CD47 blockade therapy
EP3454900A4 (en) 2016-05-09 2020-01-29 Celgene Corporation CD47 ANTIBODIES AND METHODS OF USE
CN109689684B (zh) 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
AU2017332960B2 (en) 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CN108779179B (zh) 2016-11-28 2022-02-08 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
JP7179743B2 (ja) 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
JP7170331B2 (ja) 2017-03-22 2022-11-14 アーチ オンコロジー，インコーポレイテッド 固形及び血液癌の治療のための併用療法
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
CN110958888A (zh) 2017-03-28 2020-04-03 延龄草治疗公司 Cd47阻断疗法
KR102702926B1 (ko) 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
CN118271443A (zh) 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
WO2018237168A1 (en) 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504524A (ja) 2001-06-28 2005-02-17 ドマンティス リミテッド 二重特異性リガンドとその利用
JP2015504899A (ja) 2012-01-17 2015-02-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
JP2015512034A (ja) 2012-02-15 2015-04-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー
JP2016526909A (ja) 2013-07-31 2016-09-08 アムジエン・インコーポレーテツド Ｆｃ含有ポリペプチドの安定化
JP2017525698A (ja) 2014-08-15 2017-09-07 メルク パテント ゲーエムベーハー Ｓｉｒｐ−アルファ免疫グロブリン融合タンパク質
JP2020503057A (ja) 2016-09-21 2020-01-30 エーエルエックス オンコロジー インコーポレイテッド シグナル調節タンパク質αに対する抗体及び使用方法
JP2020506727A (ja) 2017-02-06 2020-03-05 オリオンズ バイオサイエンス エヌブイ 標的化キメラタンパク質及びその使用
WO2020047326A2 (en) 2018-08-31 2020-03-05 ALX Oncology Inc. Decoy polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAPUY, Claudia I.，Resolving the daratumumab interference with blood compatibility testing，Transfusion，2015年03月12日，Vol. 55，No. 6, pt2，p.1545-1554，DOI: 10.1111/trf.13069
KIM, Tae Yeul，Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing，Transfusion，2020年08月20日，Vol. 60，No. 10，p.2399-2407，DOI: 10.1111/trf.16009
MCCUDDEN, Christopher R，Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis Tests，Clinical Chemistry，2010年12月01日，Vol. 56，No. 12，p.1897-1899，DOI: 10.1373/clinchem.2010.152116
VELLIQUETTE, Randall W.，Monoclonal anti‐CD47 interference in red cell and platelet testing，Transfusion，2018年12月05日，Vol. 59，No. 2，p.730-737，DOI: 10.1111/trf.15033

Also Published As

Publication number Publication date
US20220196651A1 (en) 2022-06-23
EP4256336A1 (en) 2023-10-11
JP2023552375A (ja) 2023-12-15
WO2022120286A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP7847587B2 (ja) 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
JP7561775B2 (ja) 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
Zou et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry
US9173943B2 (en) Imprinted polymer nanoparticles
JPS61500315A (ja) 血清中の免疫複合体を検出する方法
JP7853912B2 (ja) 免疫グロブリン検出と関連する療法
JP7853333B2 (ja) キメラ免疫グロブリン
TW201910349A (zh) 包含重組人類ｃｄ３８細胞外區域之組合物、方法及／或套組
CA2912514A1 (en) Method for predicting clinical effect of immunotherapy
JP7326108B2 (ja) 自己免疫性水疱症の診断
JPH05260990A (ja) モノクローナル抗体
Voulgaraki et al. Multivalent recombinant proteins for probing functions of leucocyte surface proteins such as the CD200 receptor
WO2023143547A1 (zh) 抗cd28抗体及其应用
JP2010523963A (ja) 診断アッセイ
EP3700923A1 (en) Phospholipase a2 receptor antigens and their medical use
WO2022133347A2 (en) Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof
WO2021242961A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
US8309091B2 (en) CEACAM8-related method for treating autoimmune diseases
Pereira et al. Soluble DC-SIGN isoforms: Ligands with unknown functions-A mini-review
CN119874914B (zh) 一种抗程序性死亡受体1的抗体a3及其应用
US20240116994A1 (en) Peptides And Use Thereof For Diagnosing And Treating Antiphospholipid Syndrome
RU2550255C2 (ru) РЕКОМБИНАНТНАЯ ДНК pA3, РЕКОМБИНАНТНАЯ ДНК pQE 30-pA3, ОБЕСПЕЧИВАЮЩИЕ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A3, ШТАММ E. coli М 15-A3, ТРАНСФОРМИРОВАННЫЙ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pQE 30-pA3 И ЭКСПРЕССИРУЮЩИЙ РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД A3, РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД A3, ОБЛАДАЮЩИЙ СПОСОБНОСТЬЮ СЕЛЕКТИВНО СВЯЗЫВАТЬ ЧСА, И ТЕСТ-СИСТЕМА РФА ДЛЯ КАЧЕСТВЕННОГО ВЫЯВЛЕНИЯ МИКРОАЛЬБУМИНУРИИ, ТЕСТ-СИСТЕМА ДЛЯ КОЛИЧЕСТВЕННОГО ОПРЕДЕЛЕНИЯ МИКРОАЛЬБУМИНУРИИ
JP4381145B2 (ja) 細胞外グラニュライシンの検出方法
Anaya et al. A multiplex extracellular interactome screening method employing high-avidity nanoparticles
WO2024239123A1 (en) Monovalent antibody blocking fc receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260407

R150 Certificate of patent or registration of utility model

Ref document number: 7847587

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150